TRC results

Stem cell; cell based hair therapy
21

» why do they want to complete both the clinical trials and commercialisation
» after phase 2 ?
»
» why not just complete the clinical trials and leave it at that ? The fact
» that they also want to complete commercialisation tells us something.

Where do they say that they plan to “complete commercialization” after phase 2?

They say the opposite:

We do not intend to finance the continuation of clinical and commercial development of ICX-TRC beyond the current Phase II trial and shall seek to sign a partner
<<<

not clinical not commercial.

22

they’re looking for a partner for TRC, whats the big deal

the same is happening with ICX SKN

“It is our intention to seek a partner to commercialise the product, as a minimum in the US market. This is likely to be achieved after the Phase II data are available”

They’ve already done this with vavaleta

23

nathan, I think you are answering in the wrong place of the thread.
Do you have “thread view” activated?

» they’re looking for a partner for TRC, whats the big deal
»
» the same is happening with ICX SKN
»
» “It is our intention to seek a partner to commercialise the product, as a
» minimum in the US market. This is likely to be achieved after the Phase II
» data are available”
»
»
» They’ve already done this with vavaleta

well, it is not the same.
For TRC, there was always a plan for commercialization partnerships,
and we didn’t complain .

But what they have said now, in the new report is different.

24

» nathan, I think you are answering in the wrong place of the thread.
» Do you have “thread view” activated?
»
» » they’re looking for a partner for TRC, whats the big deal
» »
» » the same is happening with ICX SKN
» »
» » “It is our intention to seek a partner to commercialise the product, as
» a
» » minimum in the US market. This is likely to be achieved after the Phase
» II
» » data are available”
» »
» »
» » They’ve already done this with vavaleta
»
» well, it is not the same.
» For TRC, there was always a plan for commercialization partnerships,
» and we didn’t complain .
»
» But what they have said now, in the new report is totally different.

Its not totally different, there is a line that reads:

“Intercytex has granted Bosley, the largest chain of hair transplant clinics in the US, an option to negotiate distribution rights to the product.”

which means Bosley could still end up selling a final product.

The key word for me here is Negotiate, it seems to me like Bosley have the right to put the first offer in, but ICX aren’t obligated to accept???